Key Points
- Major shareholder Bioventures 2018 L.P. Mpm sold 25,131 Entrada Therapeutics shares at an average of $7.19, generating $180,691.89 and reducing its position by 0.60% to 4.18 million shares. The shareholder also reported several additional sales in late August and early September.
- TRDA opened at $7.17, with a market capitalization of approximately $279.2 million, and remains well below its 52-week high of $16.45. The company recently missed quarterly earnings and revenue estimates, reporting a loss of $1.01 per share and $0.90 million in revenue.
- Analysts maintain a “Moderate Buy” consensus with an average price target of $17.75, although ratings range from Buy to Sell; institutional investors and hedge funds own 86.39% of the stock.
Entrada Therapeutics, Inc. (NASDAQ:TRDA - Get Free Report) major shareholder Bioventures 2018 L.P. Mpm sold 25,131 shares of the company's stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $7.19, for a total value of $180,691.89. Following the sale, the insider owned 4,177,215 shares in the company, valued at approximately $30,034,175.85. The trade was a 0.60% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Large shareholders that own 10% or more of a company's stock are required to disclose their transactions with the SEC.
Bioventures 2018 L.P. Mpm also recently made the following trade(s):
- On Thursday, September 3rd, Bioventures 2018 L.P. Mpm sold 32,263 shares of Entrada Therapeutics stock. The stock was sold at an average price of $7.17, for a total value of $231,325.71.
- On Tuesday, September 1st, Bioventures 2018 L.P. Mpm sold 29,088 shares of Entrada Therapeutics stock. The stock was sold at an average price of $7.06, for a total value of $205,361.28.
- On Monday, August 31st, Bioventures 2018 L.P. Mpm sold 44,259 shares of Entrada Therapeutics stock. The shares were sold at an average price of $6.99, for a total value of $309,370.41.
- On Friday, August 28th, Bioventures 2018 L.P. Mpm sold 3,733 shares of Entrada Therapeutics stock. The shares were sold at an average price of $7.01, for a total value of $26,168.33.
- On Thursday, August 27th, Bioventures 2018 L.P. Mpm sold 38,922 shares of Entrada Therapeutics stock. The stock was sold at an average price of $7.20, for a total value of $280,238.40.
Entrada Therapeutics Stock Down 1.8%
Shares of TRDA stock opened at $7.17 on Friday. The company has a market cap of $279.20 million, a price-to-earnings ratio of -1.81 and a beta of -0.25. Entrada Therapeutics, Inc. has a 52 week low of $5.02 and a 52 week high of $16.45. The firm has a 50 day moving average of $7.08 and a 200-day moving average of $9.20.
Entrada Therapeutics (NASDAQ:TRDA - Get Free Report) last released its quarterly earnings data on Wednesday, August 5th. The company reported ($1.01) earnings per share for the quarter, missing the consensus estimate of ($0.97) by ($0.04). Entrada Therapeutics had a negative net margin of 3,537.73% and a negative return on equity of 57.61%. The company had revenue of $0.90 million during the quarter, compared to the consensus estimate of $2.32 million. Analysts anticipate that Entrada Therapeutics, Inc. will post -4.03 earnings per share for the current year.
Analysts Set New Price Targets
Several equities research analysts have weighed in on the stock. Roth Capital reaffirmed a "buy" rating and issued a $11.00 price target on shares of Entrada Therapeutics in a research note on Wednesday, August 12th. Weiss Ratings raised shares of Entrada Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Monday. HC Wainwright downgraded Entrada Therapeutics from a "buy" rating to a "neutral" rating in a research note on Friday, May 8th. Finally, Guggenheim decreased their target price on Entrada Therapeutics from $20.00 to $17.00 and set a "buy" rating for the company in a research report on Monday, June 8th. Four equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $17.75.
Check Out Our Latest Analysis on TRDA
Institutional Trading of Entrada Therapeutics
Several hedge funds have recently bought and sold shares of the business. State of Wyoming acquired a new stake in Entrada Therapeutics in the 2nd quarter valued at $37,000. Russell Investments Group Ltd. lifted its stake in shares of Entrada Therapeutics by 72.7% in the third quarter. Russell Investments Group Ltd. now owns 8,808 shares of the company's stock valued at $51,000 after buying an additional 3,707 shares in the last quarter. Occudo Quantitative Strategies LP bought a new position in shares of Entrada Therapeutics in the second quarter valued at $68,000. Jain Global LLC bought a new position in shares of Entrada Therapeutics in the third quarter valued at $69,000. Finally, IHT Wealth Management LLC acquired a new position in shares of Entrada Therapeutics during the second quarter valued at about $72,000. Institutional investors and hedge funds own 86.39% of the company's stock.
About Entrada Therapeutics
(
Get Free Report)
Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.
The company's pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
